Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana

NEW YORK, August 19, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Humana Inc. (NYSE: HUM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5808-100free.

--
Gilead Sciences, Inc. Research Reports
On August 13, 2014, Gilead Sciences, Inc.'s (Gilead) stock moved up 0.66% to end the trading session at $93.98, following the NASDAQ Composite that moved up 1.02% over the same trading session. Gilead's stock opened the session at $93.50 and oscillated in the range of $93.34 - $94.61, thereby creating a 52-week high of $94.61. Over the past one month, the stock has returned 4.60%, outperforming the NASDAQ Composite that lost 0.14% over the same period of time. The stock is trading below its 50-day and 200-day moving averages of $94.19 and $94.15 respectively. The full research reports on Gilead are available to download free of charge at:

http://www.analystsreview.com/Aug-19-2014/GILD/report.pdf

--
Pfizer Inc. Research Reports
On August 13, 2014, Pfizer Inc. (Pfizer) announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]PCV13) for routine use to help protect adults aged 65 years and older against pneumococcal disease, which includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. The Company stated that pneumococcal pneumonia is the most common type of community-acquired bacterial pneumonia in the U.S. Susan Silbermann, President, Pfizer Vaccines, said, "As health care professionals in the US begin to implement this new ACIP recommendation, we believe that Prevnar 13 can now help prevent vaccine-type pneumococcal pneumonia in older adults and has the potential to provide an important public health benefit. Pfizer remains committed to working with the healthcare and public health communities to raise awareness of the importance of adult immunization among consumers." The full research reports on Pfizer are available to download free of charge at:

http://www.analystsreview.com/Aug-19-2014/PFE/report.pdf

--
AbbVie Inc. Research Reports
On August 13, 2014, shares in AbbVie Inc. (AbbVie) moved up 1.44% to end the day at $53.60, reversing the loss it made in its previous trading session. AbbVie's stock opened the session at $52.97 and fluctuated between $52.75 and $53.64. The stock has a 52-week high of $58.27 and a 52-week low of $42.25. Over the past six months, the stock has returned 5.66% largely in line with the S&P 500 that returned 5.88% over the same period. The full research reports on AbbVie are available to download free of charge at:

http://www.analystsreview.com/Aug-19-2014/ABBV/report.pdf

--
Express Scripts Holding Company Research Reports
On August 13, 2014, shares in Express Scripts Holding Company's (Express Scripts) ended the day 0.26% higher at $71.89, following the Dow Jones Industrial Average that moved up 0.55% over the same trading session. Share in Express Scripts opened the session at $71.55 and oscillated between $71.55 and $72.11. Over the past three months, the stock has gained 5.09% outperforming the Dow Jones Industrial Average that gained 0.23% over the same period of time. Express Scripts' stock is trading below its 50-day moving average of $71.95 and above its 200-day moving average of $71.86. The full research reports on Express Scripts are available to download free of charge at:

http://www.analystsreview.com/Aug-19-2014/ESRX/report.pdf

--
Humana Inc. Research Reports
Humana Inc. posted on the calendar of events sections of its official website that the Company will participate in the upcoming Oppenheimer Investor Meetings on August 21, 2014 in Boston, Massachusetts. The full research reports on Humana are available to download free of charge at:

http://www.analystsreview.com/Aug-19-2014/HUM/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review